Vera Therapeutics Investor Relations Material
Latest events
Study Result
Vera Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Vera Therapeutics Inc
Access all reports
Vera Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing and commercializing treatments aimed at serious immunological diseases. Their portfolio includes atacicept, a fusion protein undergoing clinical trials for immunoglobulin A nephropathy and Phase II trials for lupus nephritis. Another significant development in their pipeline is MAU868, a monoclonal antibody targeting the BK virus in transplant patients. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.
Key slides for Vera Therapeutics Inc
R&D Day 2024
Vera Therapeutics Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Vera Therapeutics Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
VERA
Country
🇺🇸 United States